Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
200 shown of 2,665 total abstracts
  1. Abstract 42832026-09-03 · 14:45 CT · S406
    ASCENT-543: Trodelvy (sacituzumab govitecan) neoadjuvant in urothelial carcinoma
    S. Peters, E. Winer, S. Modi, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 44312026-09-01 · 19:45 CT · S100A
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-923 study)
    S. Antonia, C. Saura, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  3. Abstract 92282026-09-01 · 16:15 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    H. Rugo, E. Winer, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 42252026-09-03 · 18:15 CT · E450
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-961
    T. Mok, M.C. Garassino, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 11962026-09-03 · 15:45 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-466
    M. Reck, S. Modi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract 19062026-09-02 · 14:45 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    A. Spira, P. Schmid, L. Paz-Ares, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract 44002026-09-05 · 13:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-132 study)
    R. Herbst, M. Reck, H. Rugo · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 17082026-09-03 · 15:15 CT · S406
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    J. Brahmer, A. Spira · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract 12632026-09-01 · 20:30 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-272
    R. Herbst, F. Andre · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 96352026-09-01 · 16:30 CT · E450
    Quality of life outcomes with Imfinzi in patients with NSCLC
    H. Borghaei, M. Krop · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 40772026-09-01 · 15:45 CT · E450
    EV-375: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    F. Andre, T. Mok, M.C. Garassino · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 14652026-09-04 · 15:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-971 study)
    H. Borghaei, C. Saura, N. Rizvi · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 47182026-09-02 · 19:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-342
    S. Antonia, F. Andre, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  14. Abstract 11532026-09-02 · 14:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-609
    J. Cortes, S. Modi, S. Tolaney · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract 91902026-09-03 · 20:15 CT · S100A
    Long-term follow-up of Keytruda 1L for SCLC: KEYNOTE-38
    R. Herbst, C. Robert, S. Peters, et al. · Karolinska Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  16. Abstract 18612026-09-03 · 18:00 CT · Arie Crown Theater
    DESTINY-Breast-928: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    P. Schmid, S. Peters, L. Paz-Ares, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract 19702026-09-01 · 15:15 CT · E450
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    N. Rizvi, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 48242026-09-02 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-32
    L. Paz-Ares, S. Peters, C. Robert, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  19. Abstract 65052026-09-05 · 15:45 CT · Arie Crown Theater
    KEYNOTE-536: Keytruda (pembrolizumab) neoadjuvant in RCC
    S. Antonia, M.C. Garassino, G. Curigliano, et al. · National Cancer Center Japan
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 41182026-09-03 · 19:45 CT · S100A
    Long-term follow-up of Imfinzi 3L+ for biliary tract: PACIFIC-769
    M. Krop, S. Modi, H. Rugo, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  21. Abstract 59952026-09-02 · 14:30 CT · S406
    Long-term follow-up of Lynparza 3L+ for prostate: OlympiA-479
    M. Reck, A. Spira, N. Rizvi, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  22. Abstract 13002026-09-03 · 18:15 CT · S100A
    IMpower-73: Tecentriq (atezolizumab) adjuvant in TNBC
    H. Borghaei, A. Spira, C. Saura, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 92522026-09-04 · 13:15 CT · S406
    KEYNOTE-283: Keytruda (pembrolizumab) 1L in NSCLC
    H. Borghaei, S. Tolaney, H. Rugo · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  24. Abstract 19742026-09-05 · 18:00 CT · S100A
    MONARCH-707: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Brahmer, C. Robert · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 49702026-09-04 · 21:30 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-764
    J. Brahmer, A. Spira · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract 97092026-09-05 · 13:45 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    T. Mok, M.C. Garassino, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 45912026-09-01 · 15:15 CT · E450
    PACIFIC-401: Imfinzi (durvalumab) 1L in biliary tract
    M. Krop, E. Winer · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  28. Abstract 14422026-09-04 · 16:15 CT · Hall B1
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-530
    J. Cortes, H. Borghaei · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 12492026-09-01 · 20:45 CT · E450
    MONARCH-59: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    S. Tolaney, N. Rizvi, C. Saura, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 103702026-09-05 · 16:45 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    C. Robert, M.C. Garassino, R. Herbst · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  31. Abstract 97202026-09-01 · 14:30 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with SCLC
    S. Modi, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  32. Abstract 93522026-09-03 · 15:30 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Reck, C. Robert, M.C. Garassino, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 14222026-09-04 · 18:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-692
    M. Krop, M. Reck, S. Modi, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  34. Abstract 10792026-09-01 · 16:15 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-802 study)
    S. Modi, H. Rugo · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 41892026-09-03 · 14:00 CT · E450
    Long-term follow-up of Trodelvy 1L for urothelial carcinoma: ASCENT-684
    A. Spira, M. Krop, S. Antonia · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 55402026-09-03 · 13:00 CT · S406
    OlympiA-429: Lynparza (olaparib) 2L in prostate
    C. Saura, M. Krop, F. Andre, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  37. Abstract 10792026-09-05 · 21:15 CT · S100A
    MONARCH-728: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Robert, L. Paz-Ares, R. Herbst, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 10122026-09-01 · 13:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-601
    C. Saura, H. Rugo, C. Robert, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 98182026-09-04 · 19:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-359
    R. Herbst, P. Schmid, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  40. Abstract 63572026-09-01 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for ovarian: OlympiA-956
    M. Reck, C. Robert · Peter MacCallum Cancer Centre
    Poster Discussion SessionGynecologic Cancer📄🖼️
  41. Abstract 41702026-09-02 · 19:15 CT · E450
    DESTINY-Breast-335: Enhertu (trastuzumab deruxtecan) 1L in gastric
    C. Saura, H. Borghaei, R. Herbst · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  42. Abstract 19032026-09-05 · 21:45 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-907 study)
    E. Winer, S. Antonia, A. Spira, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract 17832026-09-03 · 13:15 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    C. Robert, S. Antonia · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 61172026-09-01 · 13:00 CT · E450
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-672
    M. Krop, S. Modi, C. Saura, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 44822026-09-02 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-816 study)
    S. Antonia, T. Mok, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  46. Abstract 48802026-09-02 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-197 study)
    F. Andre, H. Borghaei, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 104532026-09-02 · 20:15 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    H. Borghaei, L. Paz-Ares, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  48. Abstract 41392026-09-04 · 18:30 CT · S406
    IMpower-931: Tecentriq (atezolizumab) neoadjuvant in HCC
    J. Cortes, T. Mok, L. Paz-Ares, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  49. Abstract 99952026-09-05 · 18:30 CT · E450
    PACIFIC-173: Imfinzi (durvalumab) 2L in SCLC
    S. Peters, N. Rizvi · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  50. Abstract 62462026-09-05 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-616 study)
    F. Andre, S. Tolaney, M.C. Garassino, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 96322026-09-02 · 19:00 CT · E450
    KEYNOTE-998: Keytruda (pembrolizumab) 1L in SCLC
    M.C. Garassino, S. Tolaney, G. Curigliano, et al. · University of Chicago
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  52. Abstract 95152026-09-05 · 19:15 CT · S100A
    PACIFIC-423: Imfinzi (durvalumab) 1L in SCLC
    P. Schmid, A. Spira, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  53. Abstract 12152026-09-03 · 13:45 CT · S100A
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-333
    J. Brahmer, E. Winer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 47772026-09-03 · 19:15 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in HCC
    F. Andre, H. Rugo · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  55. Abstract 13342026-09-01 · 20:30 CT · Hall B1
    PALOMA-315: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    J. Brahmer, S. Modi, G. Curigliano, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 44442026-09-05 · 18:45 CT · S406
    Long-term follow-up of Trodelvy adjuvant for urothelial carcinoma: ASCENT-411
    S. Peters, S. Antonia · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  57. Abstract 46682026-09-05 · 20:45 CT · S406
    ASCENT-763: Trodelvy (sacituzumab govitecan) adjuvant in urothelial carcinoma
    F. Andre, C. Robert, M.C. Garassino, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  58. Abstract 44412026-09-04 · 14:00 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    P. Schmid, M.C. Garassino · Princess Margaret Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  59. Abstract 65242026-09-02 · 19:00 CT · S406
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-894
    J. Brahmer, G. Curigliano, H. Rugo, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  60. Abstract 16892026-09-04 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    H. Borghaei, M. Krop · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  61. Abstract 48582026-09-05 · 14:00 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in gastric
    H. Borghaei, S. Modi, M.C. Garassino · MD Anderson Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  62. Abstract 19372026-09-05 · 20:30 CT · E450
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-964
    S. Modi, T. Mok · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  63. Abstract 11312026-09-05 · 19:45 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-221 study)
    C. Robert, F. Andre, T. Mok, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  64. Abstract 16752026-09-02 · 19:30 CT · S100A
    MONALEESA-349: Kisqali (ribociclib) maintenance in HR+ breast cancer
    J. Brahmer, N. Rizvi · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  65. Abstract 96782026-09-04 · 19:00 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-316 study)
    M.C. Garassino, J. Cortes, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  66. Abstract 43932026-09-01 · 18:00 CT · S406
    PACIFIC-971: Imfinzi (durvalumab) maintenance in biliary tract
    S. Tolaney, C. Saura, F. Andre · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  67. Abstract 68562026-09-03 · 16:00 CT · Hall B1
    KEYNOTE-703: Keytruda (pembrolizumab) 3L+ in RCC
    P. Schmid, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  68. Abstract 10052026-09-01 · 21:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-395 study)
    G. Curigliano, H. Borghaei · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 13062026-09-05 · 20:00 CT · E450
    DESTINY-Breast-823: Enhertu (trastuzumab deruxtecan) 1L in HR+ breast cancer
    M.C. Garassino, S. Antonia · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 16032026-09-04 · 13:15 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-731 study)
    M. Krop, G. Curigliano, C. Saura · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract 92602026-09-03 · 18:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with NSCLC
    F. Andre, M. Reck, M. Krop · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  72. Abstract 14272026-09-04 · 18:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-792
    M.C. Garassino, M. Reck, J. Cortes · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  73. Abstract 47642026-09-02 · 20:45 CT · E450
    Long-term follow-up of Opdivo 1L for HCC: CheckMate-675
    E. Winer, C. Robert · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  74. Abstract 10962026-09-05 · 15:00 CT · S100A
    MONARCH-939: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    P. Schmid, E. Winer, N. Rizvi, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 99652026-09-02 · 19:15 CT · S406
    FLAURA-134: Tagrisso (osimertinib) 3L+ in NSCLC
    P. Schmid, L. Paz-Ares, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  76. Abstract 10952026-09-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-831 study)
    H. Borghaei, N. Rizvi, R. Herbst, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 99092026-09-05 · 13:30 CT · E450
    Quality of life outcomes with Tagrisso in patients with NSCLC
    S. Antonia, G. Curigliano, J. Cortes, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  78. Abstract 10132026-09-02 · 13:30 CT · S406
    MONARCH-864: Verzenio (abemaciclib) 1L in HR+ breast cancer
    C. Robert, T. Mok, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 99492026-09-03 · 19:45 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-866
    S. Tolaney, H. Borghaei, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  80. Abstract 19232026-09-05 · 20:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-620 study)
    G. Curigliano, C. Saura, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 102022026-09-05 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-108
    L. Paz-Ares, T. Mok · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  82. Abstract 92512026-09-01 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-469 study)
    E. Winer, J. Cortes, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  83. Abstract 52352026-09-01 · 14:00 CT · E450
    Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-857
    C. Saura, L. Paz-Ares, R. Herbst, et al. · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  84. Abstract 17882026-09-01 · 18:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    M. Krop, J. Brahmer · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 48802026-09-02 · 16:45 CT · Arie Crown Theater
    EV-234: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    M.C. Garassino, P. Schmid, S. Antonia · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  86. Abstract 41522026-09-03 · 20:45 CT · E450
    PACIFIC-875: Imfinzi (durvalumab) 1L in biliary tract
    M. Reck, N. Rizvi, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  87. Abstract 94662026-09-01 · 16:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-773 study)
    E. Winer, G. Curigliano · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  88. Abstract 91962026-09-05 · 13:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-772 study)
    S. Modi, M. Reck, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  89. Abstract 44422026-09-01 · 14:15 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-479
    E. Winer, H. Rugo, J. Cortes, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  90. Abstract 14412026-09-02 · 19:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-853
    J. Brahmer, C. Saura · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract 92602026-09-03 · 15:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-874 study)
    C. Saura, M. Krop, C. Robert, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  92. Abstract 18822026-09-05 · 18:30 CT · S100A
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-835
    M.C. Garassino, A. Spira, E. Winer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 91222026-09-03 · 15:00 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-681 study)
    E. Winer, S. Modi, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  94. Abstract 16662026-09-03 · 20:45 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-684
    N. Rizvi, S. Modi · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract 14322026-09-05 · 16:30 CT · S100A
    PALOMA-729: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    S. Modi, L. Paz-Ares, C. Saura, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  96. Abstract 64792026-09-02 · 20:00 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    S. Antonia, P. Schmid, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  97. Abstract 48732026-09-02 · 16:15 CT · S406
    Long-term follow-up of Tecentriq maintenance for HCC: IMpower-881
    H. Rugo, A. Spira, L. Paz-Ares, et al. · Institut Gustave Roussy
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  98. Abstract 11022026-09-03 · 13:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-615 study)
    P. Schmid, R. Herbst, S. Peters · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  99. Abstract 47832026-09-05 · 16:45 CT · Hall B1
    EV-811: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    F. Andre, P. Schmid · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  100. Abstract 44902026-09-01 · 13:30 CT · Arie Crown Theater
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    S. Peters, R. Herbst, S. Antonia · MD Anderson Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  101. Abstract 41602026-09-01 · 16:15 CT · Hall B1
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-71
    M. Krop, J. Brahmer, E. Winer · Massachusetts General Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  102. Abstract 96122026-09-02 · 19:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-35 study)
    M.C. Garassino, S. Peters, M. Reck, et al. · Royal Marsden Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  103. Abstract 97542026-09-03 · 16:00 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    P. Schmid, C. Robert, S. Peters, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  104. Abstract 92862026-09-03 · 14:30 CT · Arie Crown Theater
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-620
    S. Tolaney, J. Brahmer, A. Spira, et al. · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  105. Abstract 92002026-09-03 · 14:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-280
    F. Andre, T. Mok · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  106. Abstract 66162026-09-02 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-741
    S. Tolaney, M. Reck, G. Curigliano · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  107. Abstract 44992026-09-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-716 study)
    M.C. Garassino, M. Reck, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  108. Abstract 11122026-09-05 · 18:30 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-510
    S. Tolaney, A. Spira, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 97742026-09-04 · 13:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-203
    F. Andre, A. Spira, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  110. Abstract 13482026-09-05 · 21:45 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    S. Peters, F. Andre, S. Modi, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 15032026-09-02 · 21:15 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-698
    L. Paz-Ares, F. Andre · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  112. Abstract 41032026-09-01 · 13:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-809
    S. Modi, N. Rizvi · Dana-Farber Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  113. Abstract 92432026-09-02 · 13:15 CT · S100A
    Quality of life outcomes with Opdivo in patients with NSCLC
    T. Mok, F. Andre, J. Cortes · Mayo Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  114. Abstract 13992026-09-01 · 21:15 CT · Hall B1
    DESTINY-Breast-298: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    J. Cortes, J. Brahmer, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  115. Abstract 98222026-09-04 · 16:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-498
    J. Cortes, T. Mok, P. Schmid, et al. · Massachusetts General Hospital
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  116. Abstract 92622026-09-03 · 15:30 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    M. Reck, S. Peters, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  117. Abstract 51702026-09-05 · 20:15 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with prostate
    C. Robert, H. Borghaei, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  118. Abstract 41522026-09-04 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-145 study)
    S. Peters, S. Antonia, T. Mok, et al. · Cleveland Clinic
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  119. Abstract 59912026-09-02 · 19:00 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-295
    M.C. Garassino, C. Robert, R. Herbst, et al. · Stanford Cancer Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  120. Abstract 68862026-09-05 · 19:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with RCC
    C. Robert, S. Antonia · Peter MacCallum Cancer Centre
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  121. Abstract 17742026-09-05 · 15:15 CT · E450
    MONARCH-915: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Saura, T. Mok · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 43432026-09-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-212 study)
    M.C. Garassino, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  123. Abstract 14682026-09-02 · 19:00 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    F. Andre, M.C. Garassino, G. Curigliano, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 10152026-09-02 · 15:15 CT · Hall B1
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-966
    J. Brahmer, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 90222026-09-03 · 15:30 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    J. Cortes, S. Tolaney, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  126. Abstract 10652026-09-05 · 20:30 CT · S100A
    MONARCH-386: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    E. Winer, R. Herbst, F. Andre, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract 57432026-09-03 · 19:00 CT · S406
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    P. Schmid, S. Peters, G. Curigliano, et al. · Karolinska Institute
    Poster Discussion SessionGynecologic Cancer📄🖼️
  128. Abstract 10422026-09-03 · 14:45 CT · Arie Crown Theater
    MONARCH-450: Verzenio (abemaciclib) 2L in HR+ breast cancer
    T. Mok, G. Curigliano, N. Rizvi · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 15582026-09-05 · 19:45 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    C. Robert, M. Krop, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  130. Abstract 18692026-09-02 · 18:15 CT · Hall B1
    IMpower-691: Tecentriq (atezolizumab) neoadjuvant in TNBC
    S. Peters, S. Antonia, C. Robert, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 47292026-09-03 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-774 study)
    M. Krop, C. Robert, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  132. Abstract 11702026-09-03 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-898
    M.C. Garassino, M. Reck, A. Spira · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  133. Abstract 52662026-09-02 · 21:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in prostate (the OlympiA-121 study)
    S. Tolaney, N. Rizvi, E. Winer · Mayo Clinic
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  134. Abstract 11352026-09-03 · 13:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-57
    J. Cortes, C. Saura, A. Spira · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 90702026-09-02 · 15:45 CT · S406
    PACIFIC-649: Imfinzi (durvalumab) adjuvant in NSCLC
    H. Rugo, C. Robert, J. Cortes, et al. · Cleveland Clinic
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  136. Abstract 45162026-09-01 · 13:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with HCC
    C. Saura, T. Mok, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  137. Abstract 46782026-09-04 · 18:00 CT · S100A
    Long-term follow-up of Enhertu 1L for gastric: DESTINY-Breast-65
    E. Winer, H. Borghaei, M.C. Garassino, et al. · National Cancer Center Japan
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  138. Abstract 57162026-09-03 · 21:00 CT · E450
    OlympiA-763: Lynparza (olaparib) 3L+ in prostate
    P. Schmid, G. Curigliano, S. Modi, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  139. Abstract 16612026-09-02 · 13:00 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-159 study)
    M.C. Garassino, S. Modi · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  140. Abstract 94132026-09-02 · 18:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-401
    S. Tolaney, S. Modi, S. Peters · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  141. Abstract 13942026-09-03 · 16:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-847 study)
    S. Antonia, L. Paz-Ares, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 48012026-09-05 · 21:00 CT · Hall B1
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-609
    R. Herbst, F. Andre, A. Spira, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  143. Abstract 40612026-09-01 · 16:15 CT · Hall B1
    EV-883: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    M.C. Garassino, P. Schmid, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  144. Abstract 61202026-09-02 · 16:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-173
    T. Mok, J. Brahmer, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  145. Abstract 48442026-09-05 · 14:00 CT · Arie Crown Theater
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-622
    F. Andre, L. Paz-Ares · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  146. Abstract 102192026-09-01 · 16:15 CT · Hall B1
    KEYNOTE-569: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    R. Herbst, F. Andre · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  147. Abstract 13752026-09-05 · 15:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-519
    F. Andre, M. Krop, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  148. Abstract 46802026-09-04 · 16:15 CT · S100A
    Long-term follow-up of Padcev 1L for urothelial carcinoma: EV-224
    M.C. Garassino, P. Schmid, J. Brahmer, et al. · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  149. Abstract 12722026-09-04 · 19:45 CT · Hall B1
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-243
    G. Curigliano, S. Antonia, M. Krop · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 99582026-09-03 · 20:15 CT · E450
    KEYNOTE-935: Keytruda (pembrolizumab) 3L+ in SCLC
    J. Brahmer, M. Reck, M. Krop, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  151. Abstract 12282026-09-05 · 21:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda adjuvant for TNBC: KEYNOTE-228
    J. Brahmer, C. Robert, G. Curigliano · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 14632026-09-05 · 13:45 CT · Hall B1
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-539
    N. Rizvi, C. Robert, S. Peters, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 97232026-09-01 · 21:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-456
    F. Andre, R. Herbst, C. Robert, et al. · Chinese University of Hong Kong
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  154. Abstract 47492026-09-03 · 18:00 CT · Hall B1
    Long-term follow-up of Padcev adjuvant for urothelial carcinoma: EV-656
    J. Cortes, S. Antonia · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  155. Abstract 15392026-09-01 · 21:15 CT · S100A
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-444
    F. Andre, R. Herbst, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  156. Abstract 92622026-09-02 · 18:45 CT · Hall B1
    FLAURA-875: Tagrisso (osimertinib) adjuvant in NSCLC
    T. Mok, E. Winer · Peter MacCallum Cancer Centre
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  157. Abstract 47682026-09-04 · 16:15 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    S. Tolaney, M. Reck, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  158. Abstract 41832026-09-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-421 study)
    M.C. Garassino, N. Rizvi, E. Winer, et al. · Royal Marsden Hospital
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  159. Abstract 98772026-09-03 · 14:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-433 study)
    S. Antonia, L. Paz-Ares, J. Cortes · National Cancer Center Japan
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  160. Abstract 99062026-09-03 · 21:00 CT · S100A
    IMpower-389: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    J. Cortes, F. Andre, L. Paz-Ares · University of Chicago
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  161. Abstract 15442026-09-01 · 15:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-265 study)
    C. Robert, N. Rizvi, S. Modi, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  162. Abstract 98802026-09-01 · 18:45 CT · S406
    KEYNOTE-367: Keytruda (pembrolizumab) maintenance in NSCLC
    S. Peters, F. Andre · Dana-Farber Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  163. Abstract 16342026-09-04 · 15:30 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-642
    F. Andre, G. Curigliano, R. Herbst, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 60342026-09-05 · 14:30 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with ovarian
    R. Herbst, C. Robert, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGynecologic Cancer📄🖼️
  165. Abstract 18332026-09-01 · 18:00 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-358
    G. Curigliano, F. Andre, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 66852026-09-04 · 19:15 CT · Hall B1
    CheckMate-686: Opdivo (nivolumab) 2L in RCC
    F. Andre, G. Curigliano · Dana-Farber Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  167. Abstract 10062026-09-04 · 16:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-22
    P. Schmid, J. Brahmer, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 98242026-09-04 · 21:15 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-256
    M. Krop, J. Brahmer, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  169. Abstract 16112026-09-03 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-52
    E. Winer, C. Saura, S. Modi, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  170. Abstract 12832026-09-02 · 15:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-719
    C. Saura, H. Borghaei, M.C. Garassino, et al. · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 14082026-09-05 · 13:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-14
    N. Rizvi, E. Winer, F. Andre, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 90272026-09-05 · 15:15 CT · S406
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-419 study)
    L. Paz-Ares, T. Mok, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  173. Abstract 58222026-09-02 · 14:00 CT · E450
    OlympiA-704: Lynparza (olaparib) adjuvant in prostate
    A. Spira, P. Schmid · Institut Gustave Roussy
    Poster Discussion SessionGenitourinary Cancer—Prostate📄🖼️
  174. Abstract 92812026-09-02 · 20:30 CT · Hall B1
    DESTINY-Breast-846: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    L. Paz-Ares, S. Antonia, H. Borghaei, et al. · MD Anderson Cancer Center
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  175. Abstract 16142026-09-03 · 21:45 CT · S100A
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-508
    S. Antonia, L. Paz-Ares, F. Andre, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 16712026-09-05 · 19:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-317 study)
    J. Cortes, S. Antonia · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 18542026-09-03 · 15:00 CT · S100A
    Quality of life outcomes with Tecentriq in patients with TNBC
    F. Andre, M. Reck · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  178. Abstract 43352026-09-03 · 15:00 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with gastric
    N. Rizvi, J. Brahmer, S. Peters, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  179. Abstract 17052026-09-01 · 20:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-320 study)
    A. Spira, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 49702026-09-04 · 21:30 CT · S406
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-683
    H. Borghaei, S. Tolaney, C. Robert, et al. · Karolinska Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  181. Abstract 16862026-09-02 · 16:00 CT · S406
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-156
    H. Rugo, P. Schmid, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  182. Abstract 41072026-09-04 · 14:15 CT · S100A
    Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-434
    S. Tolaney, H. Borghaei, P. Schmid, et al. · Stanford Cancer Institute
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  183. Abstract 98122026-09-04 · 13:45 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Tolaney, M.C. Garassino, H. Borghaei · Cleveland Clinic
    Poster Discussion SessionMelanoma📄🖼️
  184. Abstract 97432026-09-01 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda neoadjuvant for SCLC: KEYNOTE-824
    M. Reck, S. Tolaney, J. Brahmer · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
  185. Abstract 10702026-09-05 · 15:45 CT · S100A
    DESTINY-Breast-566: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    H. Borghaei, S. Modi · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  186. Abstract 18042026-09-05 · 21:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-867
    A. Spira, R. Herbst, E. Winer · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 43622026-09-02 · 13:45 CT · E450
    DESTINY-Breast-800: Enhertu (trastuzumab deruxtecan) maintenance in gastric
    J. Cortes, N. Rizvi, S. Tolaney · Cleveland Clinic
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  188. Abstract 11602026-09-01 · 18:00 CT · S406
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-543
    N. Rizvi, M. Reck, C. Robert, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 97832026-09-03 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-955 study)
    S. Peters, G. Curigliano · Karolinska Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  190. Abstract 97022026-09-04 · 20:45 CT · S406
    FLAURA-160: Tagrisso (osimertinib) maintenance in NSCLC
    S. Peters, S. Tolaney, S. Antonia · Stanford Cancer Institute
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  191. Abstract 45912026-09-01 · 19:00 CT · E450
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    H. Rugo, M.C. Garassino, N. Rizvi, et al. · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  192. Abstract 19582026-09-03 · 18:15 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-392
    A. Spira, G. Curigliano, T. Mok, et al. · National Cancer Center Japan
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 10402026-09-01 · 18:30 CT · Hall B1
    MONALEESA-491: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    L. Paz-Ares, S. Peters, J. Brahmer · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 13182026-09-04 · 21:00 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-563 study)
    G. Curigliano, C. Robert, C. Saura, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 43322026-09-02 · 14:15 CT · S100A
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-226 study)
    C. Robert, M. Krop, A. Spira, et al. · Karolinska Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  196. Abstract 18152026-09-03 · 21:15 CT · S406
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-461
    S. Tolaney, N. Rizvi · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 48182026-09-01 · 21:30 CT · S100A
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-320
    M. Krop, F. Andre, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionGastrointestinal Cancer📄🖼️
  198. Abstract 46272026-09-02 · 13:00 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-323
    S. Antonia, G. Curigliano, M. Krop, et al. · University of Chicago
    Poster Discussion SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  199. Abstract 92782026-09-04 · 19:45 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-809
    J. Cortes, G. Curigliano, J. Brahmer, et al. · Institut Gustave Roussy
    Poster Discussion SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  200. Abstract 93232026-09-03 · 21:45 CT · Hall B1
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-187
    G. Curigliano, L. Paz-Ares, R. Herbst, et al. · Mayo Clinic
    Poster Discussion SessionLung Cancer—Small Cell📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.